ECOG-ACRIN E1A11

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Closed

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Eligible for screening study DCP 001

NCT#01863550

E1A11 is closed to accrual, January 29, 2019 at 5:00pm ET.

Leave a Reply